We are live on ! Find out more
VA

VR Adviser Portfolio holdings

AUM $2.68B
1-Year Est. Return 422.73%
This Fund
S&P 500
This Quarter Est. Return
+33.86%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$680M
AUM Growth
+$169M
Cap. Flow
+$61.2M
Cap. Flow %
9%
Top 10 Hldgs %
79.62%
Holding
31
New
9
Increased
4
Reduced
4
Closed
6

Top Buys

Rank Stock Value
1
OLMA icon
Olema Pharmaceuticals
OLMA
+$72M
2
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$59.1M
3
MRNS
Marinus Pharmaceuticals, Inc
MRNS
+$19.5M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$10.2M
5
GRTX
Galera Therapeutics, Inc. Common Stock
GRTX
+$9.47M

Top Sells

Rank Stock Value
1
TRIL
Trillium Therapeutics Inc.
TRIL
+$45.6M
2
SURF
Surface Oncology, Inc. Common Stock
SURF
+$21.2M
3
CRDF icon
Cardiff Oncology
CRDF
+$18M
4
IMV
IMV Inc. Common Shares
IMV
+$17.8M
5
ALXO icon
ALX Oncology
ALXO
+$11.3M

Sector Composition

Rank Sector Weight
1 Healthcare 86.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNST
1
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$116M 17.01%
4,016,873
– –
OLMA icon
2
Olema Pharmaceuticals
OLMA
$1B
$73.9M 10.86%
+1,536,193
New +$72M
TRIL
3
DELISTED
Trillium Therapeutics Inc.
TRIL
$59.4M 8.74%
4,040,000
-3,164,577
-44% -$45.6M
KNTE
4
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$58.6M 8.62%
+1,473,014
New +$59.1M
LONA
5
LeonaBio Inc
LONA
$66.3M
$57.9M 8.52%
169,162
+17,000
+11% +$4.01M
ALT icon
6
Altimmune
ALT
$552M
$50.8M 7.46%
4,500,000
– –
KROS icon
7
Keros Therapeutics
KROS
$199M
$47.4M 6.97%
672,306
– –
MRNS
8
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$31.6M 4.64%
2,588,941
+1,396,058
+117% +$19.5M
SNDX icon
9
Syndax Pharmaceuticals
SNDX
$1.69B
$24.8M 3.65%
1,115,255
+489,545
+78% +$10.2M
RLMD icon
10
Relmada Therapeutics
RLMD
$557M
$21.4M 3.15%
668,440
– –
KURA icon
11
Kura Oncology
KURA
$800M
$18.8M 2.76%
575,000
– –
VTGN icon
12
VistaGen Therapeutics
VTGN
$9.89M
$18.2M 2.67%
+312,000
New +$7.96M
CLDX icon
13
Celldex Therapeutics
CLDX
$2.99B
$14M 2.06%
800,000
– –
SURF
14
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$13.3M 1.96%
1,442,895
-2,435,000
-63% -$21.2M
ACRS icon
15
Aclaris Therapeutics
ACRS
$726M
$12.6M 1.86%
+1,954,932
New +$8.25M
COGT icon
16
Cogent Biosciences
COGT
$6.65B
$12.2M 1.8%
1,088,817
-1
-0% -$11
ALGS icon
17
Aligos Therapeutics
ALGS
$26.2M
$11.2M 1.65%
+16,196
New +$7.89M
GRTX
18
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$9.39M 1.38%
917,860
+866,207
+1,677% +$9.47M
SPRY icon
19
ARS Pharmaceuticals
SPRY
$509M
$6.95M 1.02%
+150,000
New +$5.01M
TNGX icon
20
Tango Therapeutics
TNGX
$4.43B
$5.72M 0.84%
500,000
– –
MTCR
21
DELISTED
Metacrine, Inc. Common Stock
MTCR
$5.45M 0.8%
693,673
-450,000
-39% -$4.13M
FPRX
22
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$4.17M 0.61%
+245,122
New +$3.07M
BCAB icon
23
BioAtla
BCAB
$5.46M
$3.4M 0.5%
+2,000
New +$3.34M
TSHA icon
24
Taysha Gene Therapies
TSHA
$1.68B
$2.87M 0.42%
107,982
– –
VRDN icon
25
Viridian Therapeutics
VRDN
$2.09B
$321K 0.05%
+19,495
New +$294K
1
2

Similar funds

MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
WGI
Westwood Global Investments Boston, Massachusetts $2.68B AUM 76.4% 1-Year Est. Return
TCAM
Turtle Creek Asset Management Toronto, Ontario, Canada $2.67B AUM 0.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
HC
Henshaw Capital Woburn, Massachusetts $2.7B AUM 29.67% 1-Year Est. Return
CI
Capital International Los Angeles, California $2.7B AUM 31.08% 1-Year Est. Return
PCA
Pallas Capital Advisors Braintree, Massachusetts $2.66B AUM 22.31% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

VR Adviser's Q4 2020 Portfolio in Review

As of Q4 2020, VR Adviser held 31 positions worth $680M, up 33% from $511M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

VR Adviser deployed $61.2M of net new capital in Q4 2020, opening 9 new positions and adding to 4 existing holdings. Its largest new stake was Olema Pharmaceuticals: 1,536,193 shares worth $73.9M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 72% a quarter earlier.

On the sell side, the largest reduction was Trillium Therapeutics Inc., an estimated $45.6M trimmed.

  • VR Adviser's largest Q4 2020 buy was Olema Pharmaceuticals: 1,536,193 shares worth $73.9M.
  • VR Adviser added most to Marinus Pharmaceuticals, Inc in Q4 2020, an estimated $19.5M increase.
  • VR Adviser's biggest Q4 2020 reduction was Trillium Therapeutics Inc., cutting an estimated $45.6M.
  • VR Adviser fully exited Cardiff Oncology in Q4 2020, selling an estimated $18M.
  • VR Adviser's ten largest holdings make up 80% of its $680M portfolio in Q4 2020.
  • VR Adviser opened 9 new positions and closed 6 in Q4 2020.
  • VR Adviser's portfolio value rose 33% quarter-over-quarter to $680M.

Based on VR Adviser's 13F filing for Q4 2020, filed 12 Feb 2021.